Global drug giant boosts Boulder biotech's funding round to $150 million
The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...
Enveda Gains Backing from Sanofi to Advance AI-Driven Drug Discovery to Clinical Trials Bringing Total Series C Financing to $150M
Sanofi invests in Enveda, reaffirming the industry’s confidence in its AI drug discovery platform and ability to deliver differentiated medicines.
The Pharma Letter1d
Sanofi investment latest validation of Enveda’s potential
Enveda, a Colorado-based biotech, has received a $20 million investment from French pharma major Sanofi. According to Enveda, ...
Pharmabiz1d
Enveda gets support from Sanofi to advance AI-driven drug discovery to clinical trials
Enveda gets support from Sanofi to advance AI-driven drug discovery to clinical trials: Boulder, Colorado Friday, February 28, 2025, 16:00 Hrs [IST] Enveda, a leading biotechnolog ...
BizWest2d
Enveda adds millions to Series C haul
Boulder-based Enveda Biosciences, which uses machine learning to discover naturally occurring drug compounds, recently added ...
Le Lézard2d
Sway Medical, Inc. Announces FDA 510(k) Clearance of its Comprehensive Concussion Management System
Sway Medical, Inc., the company that created the Mobile Concussion Management category, is proud to announce that it has received FDA 510(k) clearance as a Computerized Cognitive Assessment Aid for ...
Le Lézard2d
Pykus Therapeutics Expands Patent Portfolio for PYK-2101, a First-in-class Retinal Sealant Delivery Technology
Pykus Therapeutics, Inc. ("Pykus" or the "Company"), a medical technology company dedicated to improving the lives of patients with blinding eye diseases, today announced it has secured a new patent ...
Yahoo Finance24d
Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board
Enveda has since identified asthma as a high-impact follow-on indication for ENV-294 following promising preclinical and translational data in asthma models. This expansion underscores the company ...
Joplin Globe24d
Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board
Enveda, a biotechnology company using AI to translate nature into new medicines, is proud to announce testing of its lead asset, ENV-294, in a second indication: asthma. This novel therapeutic ...
Business Insider9d
Sanofi treatment of autoimmune hemolytic anemia granted orphan status
The FDA granted orphan designation to Sanofi (SNY) US Services’ rilzabrutinib as a treatment of autoimmune hemolytic anemia, according to a post to the agency’s website. Published first on ...
Business Insider29d
Sanofi: Positioned for Strong Growth with Conservative Guidance and Strategic Initiatives
Analyst Graham Parry of Bank of America Securities reiterated a Buy rating on Sanofi (SNYNF – Research Report), boosting the price target to €123.00. Graham Parry has given his Buy rating due ...
pharmaphorum2d
A history of Sanofi
This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...